THE FAST & NON-INVASIVE BIOCAPSULE
PLATFORM FOR CONTINUOUS BIOMARKER MONITORING (CBM)
Alivecel delivers painless, non-invasive and economically feasible innovations to help enhance the quality of life for our customers and improve the overall ease of medical biomarker monitoring aimed at an overall improvement in the quality of our patient’s lives.
A single injectable biosensor (biocapsule), no bigger that a large grain of rice, is injected just under the skin in the webbing of the hand between the thumb and forefinger, in a simple one time procedure that can be done by a nurse or qualified caregiver.
The biosensor is powered wirelessly and capable of quantitative around the clock medical biomarker monitoring. The biosensor then sends real-time data to a smartphone application. This data can be shared with patient authorised healthcare providers and other family members, and provide alarms in the case of selected blood biomarker irregularities.
It's simple, painless, economically viable - at
an estimated fraction of competitive big name devices, and provides patients, doctors, and researchers with historic and real time data.
Patients will no longer have to suffer burdensome time consuming and painful monitoring outside of the comfort of their home.
To provide the ultimate biosensor monitoring platform for people the world over, that require the continuous measurement of their health biomarkers. Examples include constant biomarker monitoring for patients with chronic medical conditions, healthcare professionals, military personnel, and essential workers.
The Alivecel Continuous Biomarker Monitoring Platform will monitor chronic diseases such as:
- Early detection of heart attack conditions
- Early detection of exposure to potentially lethal viruses
- Early detection of exposure to biohazards, toxins, and neurotoxins
- Metabolic profiling
- Obstetrics oriented monitoring
- Early detection of transplant rejection (Immunotoxicity)
We are committed to developing innovative ideas in the realm of biosensors that will provide users with a non-invasive solution and complex platform for constant biomarker monitoring.
HOW WE DO IT?
Through innovation and proven practices, Alivecel solves some of the most pressing problems facing the patients we aim to serve. Alivecel utilizes a combination of synthetic biology and nanotechnology developed by both US Universities and leading researcher facilities from around the world.
Our researches have an international reach,
a global view, but a highly focused common goal. We combine the leading technologies in this field in both innovative and practical ways.
Gerard H. Bencen, Esq., is a seasoned attorney and business professional with experience in protecting and translating basic scientific discoveries into commercial products. Deep and broad experience in the pharmaceutical, allograft, and medical device fields, with particular strength in protecting, evaluating, licensing and enforcing intellectual property rights in the United States.
Gerard holds various degrees in biochemistry, biophysics and molecular biology, and past positions with Merck.
He also served as General Counsel to NASDAQ listed allograft production company RTI Surgical (RTIX), and founded Bencen & Van Dyke, PA and Patent-Arts law practices. Over the years he has supported numerous start-up companies, collaborated with University Technology Transfer offices, and investment diligence teams, to manage legal exposure, advise senior management, and successfully concluded major investment and licensing deals.
Mark Glazer is a molecular biologist, inventor, and Chief Technology Officer (CTO) at ALIVECEL LLC. He has deep experience across various fields, including genetic engineering. His main speciali-sation is in molecular and synthetic biology, combined with micro-electronics and nanotechnology. Mark also holds various scientific interests in the arising field of astrobiology. As a scientist, he’s combining different branches of science to create novelty solutions for modern problems. Mark Glazer graduated with a degree in Molecular Biology from the University of Warsaw and The Polish Academy of Sciences. Previously, as the head scientist at a private laboratory in Glasgow, Scotland - BIOCITY, he investigated new approaches for decontamination and pathogen detection in medical equipment. Previous to that, at Warsaw University, he researched regulatory segments of mRNA - called Riboswitches, that can bind to small molecules, resulting in a change in production of proteins of pathogenic bacteria. Additionally, he did research at Poland’s National Institute of Oncology - Marie Skłodowskiej-Curie. He was also the first Polish biologist to investigate “assessment of the ability of microorganisms to survive in low Earth orbit.” In his free time, Mark writes pop-science articles for Focus Magazine.
© 2019 ALIVECEL - All Rights Reserved